Single-Chain Multivalent Ligand Traps for TGF-β Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ligand traps, such as anti-ligand antibodies and soluble receptor ectodomains, face limitations in effectively modulating ligand binding to cell surface receptors due to immunogenicity, large size, and reduced potency, particularly for TGF-β superfamily ligands involved in diseases like cancer and fibrosis.
Innovation Solution
Development of single-chain multivalent ligand traps with flexible polypeptide linkers connecting structured ligand-binding domains, which do not require fusion to dimerizing moieties like coiled-coil or Fc domains, allowing for enhanced affinity and specificity by maintaining a smaller molecular size and reducing immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-ligand antibodies are used to trap and neutralize ligands, then ligand binding to cell surface receptors is effectively inhibited, but immunogenicity increases and adverse immune responses occur
Solution Approach 1:
The patent uses soluble receptor ectodomains as simplified copies of the full receptor structure, retaining only the ligand-binding capability while eliminating the immunogenic properties of complete antibodies. This allows the trap to neutralize ligands effectively without triggering adverse immune responses.
Solution Approach 2:
The soluble receptor ectodomains are designed as transient, non-immunogenic alternatives to long-lived antibodies. These shorter-lived molecules perform their neutralization function without accumulating and causing immunogenicity issues, effectively serving as disposable ligand traps.
2Reliability
If antibodies are used as ligand traps, then ligand neutralization is achieved, but molecular size increases restricting ability to reach targets outside bloodstream
Solution Approach 1:
The patent extracts only the essential ligand-binding ectodomain portion from the complete receptor structure, removing unnecessary bulky components. This extracted minimal functional unit maintains ligand neutralization capability while significantly reducing molecular size for better tissue penetration.
Solution Approach 2:
The receptor is segmented into functional domains, with only the ligand-binding ectodomain being utilized as the trap. This segmentation separates the essential function from the non-essential bulk, creating a smaller, more effective therapeutic molecule.
3Ease of manufacture
If monovalent soluble receptor ectodomains are used to antagonize ligands, then ligand binding is partially inhibited, but antagonist potency is insufficient
Solution Approach 1:
The patent merges multiple soluble receptor ectodomain units into multivalent constructs through controlled dimerization or multimerization. This combining of multiple binding units on a single molecule enables simultaneous engagement of multiple ligand molecules, dramatically enhancing antagonist potency while maintaining the simplicity of the ectodomain structure.
Solution Approach 2:
The invention creates composite multivalent receptor constructs by assembling multiple ectodomain units with specific spacing and orientation. This composite structure combines the advantages of simple ectodomain chemistry with enhanced binding avidity, achieving high potency without complex antibody structures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The single-chain multivalent ligand traps demonstrate improved potency and stability, effectively neutralizing TGF-β and other superfamily ligands, offering potential therapeutic and diagnostic applications with enhanced tissue penetration and reduced systemic distribution.
Implementation Method 1
The TGF-β superfamily includes a number of ligands of biological significance... Principal agents that target these ligands are ligand traps/antagonists that bind and sequester ligand
Implementation Method 2
single-chain multivalent ligand traps with flexible polypeptide linkers connecting structured ligand-binding domains
Implementation Method 3
effectively neutralizing TGF-β and other superfamily ligands
Data Source
AI summary
The invention provides multivalent ligand binding agents (traps) for members of the TGF-β superfamily and polypeptide linkers and methods for making and using such constructs. The traps may be used as therapeutic or diagnostic (imaging or non-imaging) agents for diseases/disorders caused by over-production/activity of the target ligand. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-β superfamily, the agent having the general structure I:(<bd1>-linker1)k-[{<bd1>-linker2-<bd2>-linker3f-}n-(<bd3>)m-(linker4-<bd4>)d]h,where:n and h are independently greater than or equal to 1;d, f, m and k are independently equal to or greater than zero;bd's are polypeptide binding domains having an affinity for the same member of the TGF-β superfamily; and,linkers are unstructured polypeptide sequences.